HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA 'Program Alignment' Means Inspections Consistency To Supplement Industry

This article was originally published in The Rose Sheet

Executive Summary

Reports are common about ORA officials not being knowledgeable about the agency's supplement manufacturing and marketing regulations or familiar with the commodity of dietary supplements, but relying on drug or food product manufacturing regulations when they inspect supplement facilities.

You may also be interested in...



Dietary Supplement Sector Warnings Jump With FDA 'Program Alignment'

Some stakeholders complained FDA inspectors unfamiliar with Part 111 inappropriately held supplement firms to drug or food product manufacturing regulations, but the agency's assignment of inspectors with greater expertise on the regulations could be turning up compliance problems in the sector that other ORA officials might have missed.

FDA's Tighter Targeting For GMP Inspections Still Leaves Consistency Gap

The number of facilities inspected for compliance with supplement GMP requirements is increasing annually as the agency meets targets set by FSMA, according to data the American Herbal Products Association presented during a webinar.

'Program Alignment' Falls Into Place: Everything You Need To Know About US FDA's New Inspectional Approach

For the medical device industry, FDA's five regional offices – Pacific, Central, Northeast, Southwest, Southeast – will be replaced by three distinct divisions across the US encompassing 20 FDA district offices on May 15. Check out the latest US map from the agency showing where the device divisions will be located, and find out what your firm will be facing at its next facility inspection.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel